FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306157649> ?p ?o ?g. }

• W4306157649 abstract "In this study, we aimed to compare the effects of metformin-based dual therapy versus triple therapy on glycemic control and lipid profile changes in Taiwanese patients with type 2 diabetes mellitus (T2DM).In total, 60 patients were eligible for participation in this study. Patients received at least 24 months of metformin monotherapy, dual therapy, or triple therapy with metformin plus linagliptin (a dipeptidyl peptidase 4 (DPP-4) inhibitor) or dapagliflozin (a sodium-glucose cotransporter-2 (SGLT2) inhibitor). Blood samples were collected from each patient, followed by evaluation of changes in their blood glucose control and lipid profile-related markers.A combination of metformin and DPP4 and SGLT2 inhibitor therapy more effectively reduced low-density lipoprotein cholesterol (LDL-C) (p = 0.016) than metformin monotherapy. A combination of metformin and DPP4 and SGLT2 inhibitor therapy more effectively improved total cholesterol (Chol, p = 0.049) and high-density lipoprotein cholesterol (HDL-C) than metformin monotherapy (p = 0.037). Metformin plus linagliptin dual therapy was more effective than metformin monotherapy in reducing glycosylated hemoglobin (HbA1C, p = 0.011). Patients who received a combination of linagliptin and empagliflozin showed a significant reduction in their fasting blood glucose (p = 0.019), HbA1c (p = 0.036), and Chol (p = 0.010) compared with those who received linagliptin dual therapy. Furthermore, patients who received metformin plus dapagliflozin and saxagliptin showed significantly reduced Chol (p = 0.011) and LDL-C (p = 0.035) levels compared with those who received metformin plus dapagliflozin.In conclusion, dual therapy with metformin and linagliptin yields similar glycemic control ability to triple therapy. Among metformin combination triple therapy, triple therapy of empagliflozin and linagliptin might have a better glycemic control ability than dual therapy of linagliptin. Moreover, Triple therapy of dapagliflozin and saxagliptin might have a better lipid control ability than dual therapy of dapagliflozin." @default.
• W4306157649 created "2022-10-14" @default.
• W4306157649 creator A5006457409 @default.
• W4306157649 creator A5027590375 @default.
• W4306157649 creator A5030953869 @default.
• W4306157649 creator A5038654420 @default.
• W4306157649 creator A5040924649 @default.
• W4306157649 creator A5051484705 @default.
• W4306157649 creator A5059470800 @default.
• W4306157649 creator A5090108407 @default.
• W4306157649 date "2022-10-14" @default.
• W4306157649 modified "2023-10-17" @default.
• W4306157649 title "Effect of metformin monotherapy and dual or triple concomitant therapy with metformin on glycemic control and lipid profile management of patients with type 2 diabetes mellitus" @default.
• W4306157649 cites W1776821951 @default.
• W4306157649 cites W1824516519 @default.
• W4306157649 cites W1965780112 @default.
• W4306157649 cites W1979251933 @default.
• W4306157649 cites W1996638018 @default.
• W4306157649 cites W2009830637 @default.
• W4306157649 cites W2076450470 @default.
• W4306157649 cites W2079980094 @default.
• W4306157649 cites W2087056784 @default.
• W4306157649 cites W2134652590 @default.
• W4306157649 cites W2135298024 @default.
• W4306157649 cites W2147774754 @default.
• W4306157649 cites W2157288306 @default.
• W4306157649 cites W2172170752 @default.
• W4306157649 cites W2172193326 @default.
• W4306157649 cites W2553627603 @default.
• W4306157649 cites W2558145946 @default.
• W4306157649 cites W2565707232 @default.
• W4306157649 cites W2603386412 @default.
• W4306157649 cites W2756246648 @default.
• W4306157649 cites W2783813405 @default.
• W4306157649 cites W2790045825 @default.
• W4306157649 cites W2790320081 @default.
• W4306157649 cites W2798130906 @default.
• W4306157649 cites W2903308693 @default.
• W4306157649 cites W3020058100 @default.
• W4306157649 cites W3021151089 @default.
• W4306157649 cites W3161777703 @default.
• W4306157649 cites W4235377734 @default.
• W4306157649 cites W9016016 @default.
• W4306157649 doi "https://doi.org/10.3389/fmed.2022.995944" @default.
• W4306157649 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36314019" @default.
• W4306157649 hasPublicationYear "2022" @default.
• W4306157649 type Work @default.
• W4306157649 citedByCount "2" @default.
• W4306157649 countsByYear W43061576492023 @default.
• W4306157649 crossrefType "journal-article" @default.
• W4306157649 hasAuthorship W4306157649A5006457409 @default.
• W4306157649 hasAuthorship W4306157649A5027590375 @default.
• W4306157649 hasAuthorship W4306157649A5030953869 @default.
• W4306157649 hasAuthorship W4306157649A5038654420 @default.
• W4306157649 hasAuthorship W4306157649A5040924649 @default.
• W4306157649 hasAuthorship W4306157649A5051484705 @default.
• W4306157649 hasAuthorship W4306157649A5059470800 @default.
• W4306157649 hasAuthorship W4306157649A5090108407 @default.
• W4306157649 hasBestOaLocation W43061576491 @default.
• W4306157649 hasConcept C126322002 @default.
• W4306157649 hasConcept C134018914 @default.
• W4306157649 hasConcept C2775887513 @default.
• W4306157649 hasConcept C2776999253 @default.
• W4306157649 hasConcept C2777180221 @default.
• W4306157649 hasConcept C2777422806 @default.
• W4306157649 hasConcept C2778763485 @default.
• W4306157649 hasConcept C2779284873 @default.
• W4306157649 hasConcept C2779306644 @default.
• W4306157649 hasConcept C2780031085 @default.
• W4306157649 hasConcept C2780282729 @default.
• W4306157649 hasConcept C2780323712 @default.
• W4306157649 hasConcept C2780473172 @default.
• W4306157649 hasConcept C2910068830 @default.
• W4306157649 hasConcept C555293320 @default.
• W4306157649 hasConcept C71924100 @default.
• W4306157649 hasConcept C90924648 @default.
• W4306157649 hasConcept C98274493 @default.
• W4306157649 hasConceptScore W4306157649C126322002 @default.
• W4306157649 hasConceptScore W4306157649C134018914 @default.
• W4306157649 hasConceptScore W4306157649C2775887513 @default.
• W4306157649 hasConceptScore W4306157649C2776999253 @default.
• W4306157649 hasConceptScore W4306157649C2777180221 @default.
• W4306157649 hasConceptScore W4306157649C2777422806 @default.
• W4306157649 hasConceptScore W4306157649C2778763485 @default.
• W4306157649 hasConceptScore W4306157649C2779284873 @default.
• W4306157649 hasConceptScore W4306157649C2779306644 @default.
• W4306157649 hasConceptScore W4306157649C2780031085 @default.
• W4306157649 hasConceptScore W4306157649C2780282729 @default.
• W4306157649 hasConceptScore W4306157649C2780323712 @default.
• W4306157649 hasConceptScore W4306157649C2780473172 @default.
• W4306157649 hasConceptScore W4306157649C2910068830 @default.
• W4306157649 hasConceptScore W4306157649C555293320 @default.
• W4306157649 hasConceptScore W4306157649C71924100 @default.
• W4306157649 hasConceptScore W4306157649C90924648 @default.
• W4306157649 hasConceptScore W4306157649C98274493 @default.
• W4306157649 hasLocation W43061576491 @default.
• W4306157649 hasLocation W43061576492 @default.
• W4306157649 hasLocation W43061576493 @default.
• W4306157649 hasLocation W43061576494 @default.
• W4306157649 hasOpenAccess W4306157649 @default.

• next